TWi Biotechnology, Inc. engages in the research and development of repositioned drugs for unmet medical needs, especially in rare diseases associated with innate immunity. The company was founded by Chih Ming Chen on July 16, 2010 and is headquartered in Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company